×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RFL – rafael holdings, inc. class b (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RFL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
04:33 pm
rfl
Rafael (NYSE:RFL) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Rafael (NYSE:RFL) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/29
04:24 pm
rfl
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Low
Report
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
10/28
04:01 pm
rfl
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
Neutral
Report
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
9/16
08:00 am
rfl
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
Medium
Report
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
9/6
12:32 am
rfl
Rafael (NYSE:RFL) was downgraded by analysts at Wall Street Zen from
Medium
Report
Rafael (NYSE:RFL) was downgraded by analysts at Wall Street Zen from
9/6
12:32 am
rfl
Rafael (NYSE:RFL) was downgraded by analysts at Wall Street Zen from
Medium
Report
Rafael (NYSE:RFL) was downgraded by analysts at Wall Street Zen from
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/2
07:32 am
rfl
Form 8-K Rafael Holdings, Inc. For: Dec 02
Low
Report
Form 8-K Rafael Holdings, Inc. For: Dec 02
11/18
06:44 am
rfl
Form DEF 14A Rafael Holdings, Inc. For: Jan 08
Low
Report
Form DEF 14A Rafael Holdings, Inc. For: Jan 08
10/31
03:07 pm
rfl
Form 3 Rafael Holdings, Inc. For: Oct 23 Filed by: GRAYSON ALAN
Low
Report
Form 3 Rafael Holdings, Inc. For: Oct 23 Filed by: GRAYSON ALAN
10/29
05:20 pm
rfl
Form 10-K Rafael Holdings, Inc. For: Jul 31
Low
Report
Form 10-K Rafael Holdings, Inc. For: Jul 31
10/29
04:37 pm
rfl
Form 8-K Rafael Holdings, Inc. For: Oct 29
Low
Report
Form 8-K Rafael Holdings, Inc. For: Oct 29
10/28
04:11 pm
rfl
Form 8-K Rafael Holdings, Inc. For: Oct 23
Neutral
Report
Form 8-K Rafael Holdings, Inc. For: Oct 23
10/28
03:13 pm
rfl
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: Polinsky David
Low
Report
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: Polinsky David
10/10
09:48 am
rfl
Form 8-K Rafael Holdings, Inc. For: Oct 10
Low
Report
Form 8-K Rafael Holdings, Inc. For: Oct 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer
18.1%
4/28 MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia 13.6%
6/25 Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries 9.7%
12/5 Rafael Holdings to Present at LD Micro Main Event 9.3%
1/23 LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs 9.0%
11/21 Form DEF 14A Rafael Holdings, Inc. For: Jan 15 6.5%
12/3 Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition 6.4%
1/13 Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 4.2%
9/24 Form 4 Rafael Holdings, Inc. For: Sep 23 Filed by: Polinsky David 4.0%
5/16 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala 3.4%
4/28 MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia 13.6%
6/25 Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries 9.7%
12/5 Rafael Holdings to Present at LD Micro Main Event 9.3%
1/23 LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs 9.0%
11/21 Form DEF 14A Rafael Holdings, Inc. For: Jan 15 6.5%
12/3 Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition 6.4%
1/13 Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 4.2%
9/24 Form 4 Rafael Holdings, Inc. For: Sep 23 Filed by: Polinsky David 4.0%
5/16 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala 3.4%
TOP News Decliners
9/17
Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
-6.7%
8/8 Form 8-K Rafael Holdings, Inc. For: Aug 07 -6.3%
3/3 Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer -5.9%
5/13 Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations -5.5%
11/7 Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership -5.0%
3/5 Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results -4.8%
9/26 Form 8-K Rafael Holdings, Inc. For: Sep 23 -4.4%
12/9 Form 8-K Rafael Holdings, Inc. For: Dec 09 -4.2%
4/22 Form 4 Rafael Holdings, Inc. For: Apr 20 Filed by: JONAS HOWARD S -3.8%
10/2 Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer -3.4%
8/8 Form 8-K Rafael Holdings, Inc. For: Aug 07 -6.3%
3/3 Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer -5.9%
5/13 Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations -5.5%
11/7 Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership -5.0%
3/5 Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results -4.8%
9/26 Form 8-K Rafael Holdings, Inc. For: Sep 23 -4.4%
12/9 Form 8-K Rafael Holdings, Inc. For: Dec 09 -4.2%
4/22 Form 4 Rafael Holdings, Inc. For: Apr 20 Filed by: JONAS HOWARD S -3.8%
10/2 Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: